“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
"Artificial Intelligence is a tool that really levels up and creates almost like an equity for everybody to participate and, when used effectively, to...
On today’s podcast, host Wayne Bowden, Vice President of Partnerships and Strategy at Biorasi, talks with Marianne Clancy, Executive Director at Cure HHT, about...